A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds

A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the most pressing medical and socioeconomic challenge. Constituting important correlates of protection, the determination of virus-neutralizing antibodies (NAbs) is indispe...

Full description

Bibliographic Details
Main Authors: Lara Schöler, Vu Thuy Khanh Le-Trilling, Mareike Eilbrecht, Denise Mennerich, Olympia E. Anastasiou, Adalbert Krawczyk, Anke Herrmann, Ulf Dittmer, Mirko Trilling
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
COVID-19
neutralizing
antibodies
vaccine
interferon
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.573526/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.573526/full

Similar Items